Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

Osteoporosis Clinical Trial

Official title:

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03710889
• Other study ID #: BA058-05-020
• Status: Completed
• Phase: Phase 3
• Start date: September 20, 2018
• Est. completion date: July 15, 2020

Study information

• Verified date: October 2021
• Source: Radius Health, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to measure the early effects of abaloparatide on tissue-based bone formation using samples obtained by transiliac crest bone biopsy after quadruple fluorochrome labeling.

Description:

This was an open-label, single-arm study of postmenopausal women with osteoporosis treated with 80 micrograms (μg) abaloparatide for 3 months. Transiliac bone biopsies were taken at 3 months after quadruple fluorochrome labeling. The treatment duration of 3 months was determined to be the optimal time when biochemical markers of bone turnover peak and are predictive of subsequent changes in bone mineral density (BMD). The main study was conducted for a 3-month treatment period with a 1-month follow up. A sub-study was conducted at 1 site to collect peripheral quantitative computed tomography (pQCT) data. Study treatment for participants in the sub-study was extended for an additional 3 months of study drug administration for a total of 6 months of treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: July 15, 2020
• Est. primary completion date: July 15, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria Participants must meet all of the following criteria to be eligible to participate in this

study:

1. The participant is a healthy ambulatory postmenopausal female from 50 to 85 years of age (inclusive) with osteoporosis.

2. The participant has been postmenopausal for at least 5 years. Postmenopausal status will be established by a history of amenorrhea for at least 5 years and by an elevated follicle stimulating hormone (FSH) value of =30 international units(IU)/liter (L).

3. The participant has a BMD T-score =-2.5 at the lumbar spine (L1-L4) or hip (femoral neck or total hip) by dual-energy x-ray absorptiometry (DXA) or lumbar spine or hip BMD T-score =-2.0 with a history of low trauma vertebral, forearm, humerus, sacral, pelvic, hip, femoral, or tibial fracture sustained within 5 years prior to enrollment. These fractures must be documented by radiograph or hospital report.

4. The participant is in good general health as determined by medical history and physical examination (including vital signs), has a body mass index (BMI) of 18.5 to 33, inclusive, and is without evidence of clinically significant abnormality in the opinion of the Investigator.

5. The participant has serum calcium (albumin-corrected), parathyroid hormone (PTH) (1-84), phosphorus, and alkaline phosphatase levels all within the normal range during the Screening Period. Any participant with an elevated alkaline phosphatase value, and who meets all other entry criteria, is required to have a normal bone-specific alkaline phosphatase result to be enrolled.

6. The participant has serum 25-hydroxyvitamin D values = 20 nanograms (ng)/milliliter (mL) and within the normal range. Participants with serum 25-hydroxyvitamin D levels < 20 ng/ml may be treated with vitamin D3 and re-tested once.

7. The participant's resting 12-lead electrocardiogram (ECG) obtained during screening shows no clinically significant abnormality.

8. The participant has read, understood, and signed the written informed consent form. Exclusion Criteria: Participants with any of the following characteristics are not eligible to participate in

the study:

1. Presence of abnormalities of the lumbar spine that would prohibit assessment of lumbar spine BMD, defined as having at least 2 radiologically evaluable vertebrae within L1-L4.

2. Unevaluable hip BMD or participants who have undergone bilateral hip replacement (unilateral hip replacement is acceptable).

3. History of bone disorders (for example, Paget's disease) other than postmenopausal osteoporosis.

4. Clinically significant abnormality of serum hemoglobin, hematocrit, white blood cells (WBC) and platelets, coagulation, or usual serum chemistry: electrolytes, renal function, liver function and serum proteins.

5. Unexplained elevation of serum alkaline phosphatase.

6. History of radiotherapy (radiation therapy), other than radioiodine.

7. History of bleeding disorder that would preclude a bone biopsy, in the opinion of the Investigator.

8. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or immunologic, emotional and/or psychiatric disturbances to a degree that would interfere with the interpretation of study data or compromise the safety of the participant.

9. History of Cushing's disease, hyperthyroidism, hypo- or hyperparathyroidism, or malabsorptive syndromes within the past year.

10. History of significantly impaired renal function (serum creatinine > 177 micromoles [µmol]/L or >2.0 milligrams [mg]/deciliter [dL]). If the serum creatinine is >1.5 and = 2.0 mg/dL, the calculated creatinine clearance (Cockcroft-Gault) must be = 30 mL/minute (min).

11. History of any cancer within the past 5 years (other than basal cell or squamous cell cancer of the skin).

12. History of osteosarcoma at any time or a history of hereditary disorders which could predispose the participant to osteosarcoma.

13. History of nephrolithiasis or urolithiasis within the past 5 years.

14. Participant known to be positive for hepatitis B, hepatitis C, or human immunodeficiency virus infection (HIV-1 or HIV-2). Testing is not required in the absence of clinical signs and symptoms suggestive of HIV infection or acute or chronic hepatitis.

Related Conditions & MeSH terms

• Osteoporosis
• Osteoporosis Fracture
• Osteoporosis Localized to Spine
• Osteoporosis of Vertebrae
• Osteoporosis Risk
• Osteoporosis Senile
• Osteoporosis Vertebral
• Osteoporosis, Age-Related
• Osteoporosis, Postmenopausal
• Osteoporotic Fractures

Intervention

Drug:
• Abaloparatide
Abaloparatide is a novel, synthetic, 34 amino acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein (PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH[1-34] and 76% homology to human PTHrP[1-34].

Locations

Country	Name	City	State
United States	Harvard Medical School	Boston	Massachusetts
United States	Henry Ford Health System	Detroit	Michigan
United States	Center for Advanced Research & Education	Gainesville	Georgia
United States	Panorama Orthopedics & Spine Center	Golden	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
Radius Health, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin Proc. 2017 Feb;92(2):200-210. doi: 10.1016/j.mayocp.2016.10.009. — View Citation

Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology. 2016 Jan;157(1):141-9. doi: 10.1210/en.2015-1726. Epub 2015 Nov 12. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3	Change in dynamic histomorphometry indices was assessed in the cancellous envelope.	Baseline (Day 1), Month 3
Secondary	Change From Baseline in Bone Formation Rate/Bone Surface (BFR/BS) in the Cancellous Envelope at Month 3	Change in dynamic histomorphometry indices was assessed in the cancellous envelope. BFR/BS was reported as cubic millimeter/square millimeter/year (mm^3/mm^2/year).	Baseline (Day 1), Month 3
Secondary	Change in Serum Procollagen Type I N-terminal Propeptide (s-P1NP) From Baseline at Month 1 and Month 3	Blood samples were taken to measure efficacy related markers of bone metabolism at Day 1, Month 1, and Month 3.	Baseline (Day 1), Months 1 and 3
Secondary	Change in Serum Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen (s-CTX) From Baseline at Month 1 and Month 3	Blood samples were taken to measure efficacy-related markers of bone metabolism at Day 1, Month 1, and Month 3.	Baseline (Day 1), Months 1 and 3